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BACKGROUND: We investigated prognostic factors (PFs) for 90-day mortality in a large cohort of advanced/metastatic soft tissue
sarcoma (STS) patients treated with first-line chemotherapy.
METHODS: The PFs were identified by both logistic regression analysis and probability tree analysis in patients captured in the Soft
Tissue and Bone Sarcoma Group (STBSG) database (3002 patients). Scores derived from the logistic regression analysis and
algorithms derived from probability tree analysis were subsequently validated in an independent study cohort from the French
Sarcoma Group (FSG) database (404 patients).
RESULTS: The 90-day mortality rate was 8.6 and 4.5% in both cohorts. The logistic regression analysis retained performance status
(PS; odds ratio (OR)¼3.83 if PS¼1, OR¼12.00 if PS X2), presence of liver metastasis (OR¼2.37) and rare site metastasis
(OR¼2.00) as PFs for early death. The CHAID analysis retained PS as a major discriminator followed by histological grade (only for
patients with PS X2). In both models, PS was the most powerful PF for 90-day mortality.
CONCLUSION: Performance status has to be taken into account in the design of further clinical trials and is one of the most important
parameters to guide patient management. For those patients with poor PS, expected benefits from therapy should be weighed up
carefully against the anticipated toxicities.
British Journal of Cancer (2011) 104, 1544–1550. doi:10.1038/bjc.2011.136 www.bjcancer.com
Published online 19 April 2011
& 2011 Cancer Research UK
Keywords: soft tissue sarcoma; early death; prediction
                                                              
Soft tissue sarcomas (STSs) account for approximately 1 to 2% of
all adult cancers. Although local control can be obtained through
the use of surgery plus radiotherapy, up to 50% of patients will
recur at distant sites (Clark et al, 2005). At the metastatic stage,
palliative chemotherapy can be considered as a reasonable option
in the majority of cases. Both ifosfamide and doxorubicin are the
best single agents with activity in the treatment of STS. In general,
the toxicities are manageable but real, thereby making treatment
difficult (Sleijfer et al, 2005; Benjamin 1987). However, most if not
all patients will ultimately relapse and die of their disease. The
median overall survival (OS) is actually B12 months and the
median time to progression is B3 months. Regarding these facts,
three options could be considered for the treatment of patients
with advanced/metastatic STS: (1) the combination of doxorubicin
and ifosfamide if resection of metastasis looks feasible or in the
case of symptomatic patients with rapidly progressing tumours
(2) single-agent chemotherapy and (3) exclusive best supportive
care (Blay et al, 2003; Benjamin 1987). In the everyday practice,
many factors are integrated in the decision-making process:
general condition of patient, underlying co-morbidities, medical
history, resectability of metastasis, patient choice and knowledge
of prognostic factors (PFs).
One of the most important factors that should be taken into
account is the risk that a patient will die early after initiation of
treatment. Particularly in patients with a high risk of dying early, it
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sis likely that best supportive care should be preferred over
systemic therapy with its accompanying toxicities.
In addition to patient care, insight into factors associated with
early death after initiation of treatment is crucial for the design of
studies, as the lack of reliable guidance for the life expectancy
prediction is likely to introduce some biases in these clinical
studies. Moreover, the known PFs for outcome have to be taken
into account in the design of clinical trials, for example, as
stratification factors at entry for randomised clinical trials (Simon
and Altman, 1994).
The literature shows that life expectancy is most often
overestimated, which frequently results in overtreatment (Maltoni
et al, 1994; Christakis and Lemont, 2000; Penel et al, 2008;
Cle ´ment-Duche ˆne et al, 2010). For example, despite the fact that a
life expectancy of o3 months is an exclusion criterion for all phase
I studies, without reliable guidance, B20–30% of patients enroled
in phase 1 trials in expert centres died within the first 90 days
(Arkenau et al, 2008, 2009; Penel et al, 2008). Despite the high need
for models establishing the risk for early death and a large body of
literature on prognostic models for cancer patients, only few of
these models are suitable for daily decision making. Before
implementation in clinical practice, such prognostic models need
to be identified and subsequently validated in independent series.
Additionally, such models should be robust and simple, in order to
be easily applied in daily practice.
Regarding the severity of advanced STS and the limited
therapeutic options, we carried out a retrospective exploratory
analysis to (1) develop prognostic models for early death in such
population and (2) then validate the models in an independent
data set. For the purpose of this study, two complementary
approaches were used for the development of the models (scoring
system derived from logistic regression analysis and algorithm
derived from decision-tree analysis). The models were developed
with the Soft Tissue and Bone Sarcoma Group (STBSG) data set
and subsequently validated with the French Sarcoma Group (FSG)
data set.
MATERIALS AND METHODS
Data sets
We used two data sets. The first one was formed by the STBSG and
includes patients treated with single agents and combination
regimens as first-line treatments between January 1976 and
October 2001. The second one had been built by the FSG and
includes patients treated with combination regimen (MAID and
intensified-MAID) between January 1994 and October 2008
(Fayette et al, 2009; Bui et al, 2009).
Primary end point
The primary end point was 90-day mortality (early death). This
threshold is believed to be relevant in decision making for
advanced cancer patients in whom the choice of whether to treat
with chemotherapy or best supportive care need to be discussed
(Sessa et al, 1996; Geraci et al, 2006; Kelly et al, 2007; Penel et al,
2009).
Development of the models
The development of these models used the STBSG database. The
potential PFs were: gender, age, performance status (WHO-PS),
histological subtypes (angiosarcoma, fibrosarcoma, leiomyosar-
coma, malignant histiocytofibroma, malignant peripheral sheath
nerve tumour, rhabdomyosarcoma, synovial sarcoma, unclassified
STS and unknown subtype and a group containing the remaining
rare subtypes), histological grade, tumour location (abdominal,
breast, gynaecological, head and neck, lower limbs, skin, trunk
upper limbs, visceral, other locations and unknown), time interval
since initial diagnosis of STS and start of systemic therapy,
presence of lung metastasis, presence of liver metastasis, presence
of bone metastasis and presence of other metastases. Two
continuous variables (age and time interval since initial diagnosis
of STS) were recorded according to the observed quartiles. All
these items were collected in both databases.
Two complementary approaches of logistic regression analysis
and classification analysis (CHAID) (Melchior et al, 2001; Barton
et al, 2005; Chan et al, 2006; Ambalavanan et al, 2006; Courville
et al, 2009) were used for development of the prognostic models
(scoring system and decision tree, respectively).
Separate logistic regression analysis with stepwise selection of
variables (at Po0.05) identified variables in the entire STBSG
cohort associated with early death. The odds ratios (ORs) from the
logistic regression model were converted into points by dividing
by the smallest OR for any given other OR. Next, an overall score
was assigned to each patient by summing the points they received
for each of the PFs.
In the current study, CHAID was used as a complementary
method; this technique uses a systematic algorithm to detect the
stronger association between potential PFs (named ‘splitter’) and
the outcome variable (e.g., early death). Step by step, the CHAID
algorithm recursively partitions data into mutually exclusive,
exhaustive subsets that are maximally different in the dependent
variable (e.g., early death), as assessed with the use of Bonferroni-
adjusted w
2 statistics. The CHAID algorithm consisted, herein, in
three successive actions: (1) merge the subgroups with similar
occurrence of target variable (amerge¼0.01), (2) split the
subgroups using the best PF (asplitt¼0.01) and (3) terminate the
tree when the observed number of early death was B30 (Melchior
et al, 2001; Barton et al, 2005; Chan et al, 2006; Ambalavanan et al,
2006; Courville et al, 2009).
Furthermore, the prognostic accuracy (and its 95% confidence
intervals (95% CIs)) was tabulated for both models (scoring system
and decision-tree analysis) using a classical 2 2 table. The
optimal threshold for each prognostic model was established using
classical receiver operating characteristics analysis to maximise
both sensitivity and specificity (Linden 2006). The accuracy is
basically the rate of well-classified patients.
Validation and head-to-head comparison of both models
Both models were applied to the independent data set (FSG
database). The score was calculated for each patient according to
the observed presence of PFs (a patient with any missing source
variable was given a missing value of score). The entire population
was split according to the proposed CHAID algorithm. Perfor-
mance of both models had been established using area under
receiver operator curve and accuracy as previously specified.
RESULTS
Patient characteristics
The main patient characteristics are depicted in Table 1. The
STBSG cohort included 3002 patients; 2898 (96.5%) of them were
assessable for the early death rate. The rate of early death was 251
out of 2898 (8.6% (95% CI: 7.6–9.6)). In this cohort, the median
OS was 348 days. Out of the 404 patients from the FSG cohort, 399
(98.7%) were assessable for the early death rate. The rate of early
death was 18 out of 399 (4.5% (2.4–6.5)). The median OS of this
cohort was 788 days.
Development of the scoring system
The following parameters were associated with the risk of early
death in univariate analysis: age X60 (OR¼1.77, P¼0.003),
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time interval since the initial diagnosis of sarcoma X540 days
(OR¼0.41, Po0.0001), presence of liver metastasis (OR¼2.37,
P¼0.0041) and presence of other metastases (OR¼2.00,
P¼0.0061; Table 2). The final logistic regression analysis retained
the following PFs for early deaths: PS¼1( Po0.0001), PS X2
(Po0.0001), presence of liver (P¼0.0014) or other metastases
(P¼0.0055). For the attribution of points in the scoring system,
each adjusted OR was divided by the smallest one, which appeared
to be the presence of metastases other than lung, bone and liver
with an OR of 2.0. Thus, PS¼1 then gave 2 points (3.83/2.00), PS
X2 gave 6 points (12.00/2.00), presence of liver metastasis gave
1 point (2.37/2.00) and presence of other metastases also gave 1
point (2.00/2.00). As a result, the sum of points ranged from 0 to 8
and the risk of early death from 3 to 40% (Table 3). The area under
receiver operator curve was 0.69 (0.66–0.73). The optimal thresh-
old of this scoring system was set at 3. Using this threshold, the
prognostic accuracy was 91.0% (90.5–0.92.7), the positive
predictive value was 22.0% (17.3–27.3) and the negative predictive
value was 88.7% (87.4–89.4).
Development of the decision tree
The CHAID analysis provided a very simple algorithm. In the
decision tree, the most powerful discriminator (splitter) was the
PS; three subsets of patients were discriminated with increasing
risk of early death: patients with PS¼0 (early death rate: 3.3%),
patients with PS¼1 (early death rate: 9.4%) and patients with PS
X2 (early death rate: 25.5%). There was no discriminator able to
split the two first categories of patients. In the development data
set, among patients with PS X2, the histological grade was able to
individualise two subsets of patients; when the grade was 3, the
rate of early was 36.3% and in the other situations, the rate of early
death was 19.5% (Figure 1).The area under the receiver operator
curve was 0.67 (0.64–0.71). The optimal classification was based
on the separation of patients with PS¼(0–1) from other patients
(Table 4). Using this classification, the prognostic accuracy
was 86.2% (84.5–87.4), the positive predictive value was 25.3%
(20.4–30.1) and the negative predictive value was 93.3% (92.0–94.6).
Validation and head-to-head comparison of both models
Both models were applied to the FSG cohort. The scoring system
was applicable to 249 out of 404 patients (61.6%). In this cohort,
the area under receiver operator curve was 0.68 (0.52–0.83). In this
validation cohort, the prognostic accuracy of this scoring system,
with a threshold set at 3, was 67.7%. The CHAID algorithm was
applicable to 347 out of 404 patients (85.9%). Among patients with
PS X2, the rates of early death were similar whatever the
histological grade. In this cohort, the area under receiver operator
curve was 0.72 (0.58–0.86). In this validation cohort,
the prognostic accuracy of the CHAID algorithm was 89.0%
(86.5–93.5). In the development cohort, the prognostic accuracy of
the CHAID algorithm was superior to the one of the scoring.
Because PS appears as the most important PF in both models, we
evaluated the accuracy of PS as a PF for early death (see Figure 2).
In the validation cohort, the area under the receiver operator curve
of PS was similar to both other models: 0.72 (0.58–0.86).
DISCUSSION
In both cohorts consisting of patients who were treated in the
context of clinical trials with clear predefined eligibility criteria,
the rates of early death were relatively low (8.6 and 4.5%). The rate
of early death was significantly lower in the most recent trials (the
French Sarcoma Group ones) that explored the role of poly-
chemotherapy (MAID regimen) and the role of intensive
chemotherapy. Hence, it is not surprising that the rate of early
death was lower in trials with more stringent eligibility criteria. We
have observed that the rate of early death in this population is
Table 1 The characteristics of patients in both cohorts
Categorical variables
STBSG FSG
Parameters Categories Cases (%) Cases (%)
Gender Unknown 78 (2.6) 0 (0)
Men 1464 (48.8) 192 (47.6)
Women 1460 (48.6) 211 (52.4)
Performance status Unknown 140 (4.7) 49 (12.2)
0 1201 (40.0) 166 (41.2)
1 1361(45.3) 157 (39.0)
2 295 (9.8) 31 (7.7)
3 5 (0.2) 0 (0)
Interval Unknown 243 (8.1) 50 (12.3)
0–60 days 841 (28.0) 274 (67.9)
61–180 days 473 (15.8) 0 (0)
181–540 days 723 (24.1) 0 (0)
4540 days 722 (24.1) 80 (19.8)
Histological subtypes Unknown 177 (5.9) 0 (0)
Angiosarcoma 120 (4.0) 17 (4.2)
Fibrosarcoma 178 (5.9) 8 (2.0)
Leiomyosarcoma 907 (30.2) 108 (26.8)
Liposarcoma 260 (8.7) 44 (10.9)
MHF 303 (10.1) 20 (5.0)
MPNST 144 (4.8) 16 (4.0)
Other 292 (9.7) 68 (16.9)
Rhabdomyosarcoma 104 (3.5) 22 (5.5)
Synovial sarcoma 249 (8.3) 34 (8.4)
Unclassified 268 (8.9) 66 (16.4)
Grade Unknown 1122 (37.4) 25 (6.2)
I 267 (8.9) 20 (5.0)
II 707 (23.6) 107 (26.6)
III 906 (30.2) 177 (43.0)
Not applicable 0 (0) 74 (18.4)
Location Unknown 1068 (35.6) 1 (0.2)
Abdominal 409 (13.6) 67 (16.6)
Breast 23 (0.8) 0 (0)
Gynaecological 281 (9.4) 56 (13.9)
Head and neck 78 (2.6) 18 (4.5)
Lower limbs 507 (16.9) 138 (34.2)
Other 18 (0.6) 8 (2.0)
Skin 15 (0.5) 2 (0.5)
Trunk 231 (7.7) 23 (6.9)
Upper limbs 170 (5.7) 31 (7.7)
Visceral 202 (6.7) 54 (13.4)
Lung met. Unknown 134 (4.5) 125 (31.0)
No 1280 (42.6) 86 (21.3)
Yes 1588 (52.9) 192 (47.6)
Liver met. Unknown 270 (9.0) 125 (31.0)
No 2211 (73.7) 230 (57.1)
Yes 521 (17.4) 48 (11.9)
Bone met. Unknown 602 (20.1) 126 (31.3)
No 2122 (70.7) 240 (59.6)
Yes 278 (9.3) 37 (9.2)
Other met. Unknown 639 (21.3) 126 (31.3)
No 1329 (44.3) 240 (59.6)
Yes 1034 (34.4) 37 (9.2)
Previous chemotherapy Unknown 129 (4.3) 0 (0)
No 2825 (94.1) 404 (100)
Yes 48 (1.6) 0 (0)
Abbreviations: STBSG¼Soft Tissue and Bone Sarcoma Group; FSG¼French
Sarcoma Group; MHF¼malignant histiocytofibroma; MPNST¼malignant peripheral
nerve sheath tumour; met.¼metastasis.
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Univariate analysis Multivariate analysis
Parameters RR (e
b) 95% CI P-value RR (e
b) 95% CI P-value
Age
40–49 vs o40 1.32 0.87–2.00 0.1816
50–59 vs o40 1.41 0.95–2.08 0.8450
X60 vs o40 1.77 1.21–4.61 0.0030
Gender: female vs male 1.04 0.80–1.35 0.7586
Performance status
1 vs 0 3.04 2.11–4.36 o.0001 3.83 2.06–7.12 o.0001
2–3 vs 0 10.00 6.62–14.82 o.0001 12.00 5.53–26.06 o.0001
Interval
a
Q2 vs Q1 0.80 0.55–1.17 0.2618
Q3 vs Q1 0.87 0.63–1.20 0.4528
Q4 vs Q1 0.41 0.27–0.61 o.0001
Histological subtype
MFH vs leiomyo 1.32 0.82–2.10 0.244
Fibro vs leiomyo 0.59 0.21–1.68 0.325
Lipo vs leiomyo 0.72 0.38–1.33 0.314
Angio vs leiomyo 0.94 0.36–2.44 0.899
Syno vs leiomyo 0.23 0.08–0.65 0.005
MPNST vs leiomyo 0.48 0.21–1.07 0.074
Rhabdo vs leiomyo 0.95 0.59–1.15 0.818
Unclassified vs leiomyo 1.20 0.65–2.21 0.558
Other vs leiomyo 0.91 0.40–2.06 0.826
Grade
II vs 1.39 0.77–2.95 0.2749
III v I 1.99 1.13–3.49 0.0164
Primary site
Head/neck vs limb 1.88 0.88–4.00 0.1029
Trunk vs limb 1.54 1.03–2.30 0.0338
Viscera vs limb 1.61 1.06–2.45 0.0249
Lung met.: yes vs no 1.07 0.83–1.40 0.5706
Liver met.: yes vs no 1.57 1.19–2.14 0.0041 2.377 1.39–4.05 0.0014
Bone met.: yes vs no 1.13 0.73–1.74 0.5690
Other met.: yes vs no 1.50 1.12–2.01 0.0061 2.002 1.22–3.27 0.0055
Abbreviations: CI¼confidence interval; RR¼relative risk; MHF¼malignant histiocytofibroma; MPNST¼malignant peripheral nerve sheath tumour; met.¼metastasis.
aQ1: 0–60 days; Q2: 61–180 days; Q3: 181–540 days; and Q4:4540 days.
Table 3 Early death rates according to the score and score accuracy in both cohorts
STBSG data set FSG data set
Score n Early death (%) n Early death (%)
0 472 11 (3) 68 1 (1.4)
1 408 13 (4) 46 0 (0)
2 564 46 (8) 53 4 (7.5)
3 508 51 (10) 54 3 (5.5)
4 110 15 (14) 7 0 (0)
6 74 18 (25) 7 0 (0)
7 100 26 (26) 13 3 (23)
8 26 10 (40) 1 0 (0)
Area under receiver operator curve 0.91 (0.90–0.93) 0.68 (0.62–0.73)
STBSG (n¼2262) FSG (n¼249)
Early death Other Early death Other
Score X3 69 241 6 76
Score o3 121 1831 5 162
Accuracy (%) (95% CI) 91.0 (90.5–92.7) 67.7 (61.9–73.6)
Abbreviations: STBSG¼Soft Tissue and Bone Sarcoma Group; FSG¼French Sarcoma Group; CI¼confidence interval.
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trials (B16%) or in patients with carcinoma of unknown primary
(30%) (Geraci et al, 2006; Kelly et al, 2007; Arkenau et al, 2008;
Penel et al, 2008, 2009; Ferte ´ et al, 2010). The present analysis
shows that PS is the most powerful PF for early death among
patients with advanced STS treated with first-line systemic
therapy. Using two complementary approaches, we developed
and validated two prognostic models, which were however
essentially based on the assessment of PS. The scoring system
was more complex, incorporating three parameters, and was
therefore available in a more limited part of the study population.
The CHAID algorithm was based on twp variables (PS and
histological grade) and was available in a larger proportion of
patients. The implementation of the CHAID algorithm to the
validation data set had showed that the second splitter (histological
grade) did not improve the discrimination obtained with the first
splitter (PS). Lastly, the prognostic performance of PS alone was as
good as both other more sophisticated models (Figure 2).
The list of factors associated with early death identified in the
present study is not surprising, and most of the identified factors
have previously been revealed in other advanced STS databases as
being related to outcome. The impact of presence of extra-
pulmonary and especially liver metastasis had been mentioned as a
PF for OS in non-pretreated patients (Karavasilis et al, 2008; Ray-
Coquard et al, 2009). Grade has also been identified as a PF for OS
in non-pretreated patients (Antman et al, 1993). The time interval
since the initial diagnosis of STS has been identified as a PF for OS
in non-pretreated patients by Maurel et al (2009). Performance
status appeared as a PF for OS in most studies (Borden et al, 1987;
Karavasilis et al, 2008; Maurel et al, 2009; Ray-Coquard et al, 2009).
Early death
251/2898
(8.6%)
PS=0
40/1201
(3.3%)
PS=0
1/165
(0.6%)
PS=1
11/156
(7.1%)
PS=1
129/1361
(9.4%)
Grade III
40/110
(36.3%)
Grade III
1/10
(10.0%)
Non-Grade III
38/195
(19.5%)
Non-Grade III
2/16
(12.5%)
Early death
18/399
(4.5%)
PS=2
3 out of 26
(11.6%)
PS2
78/305
(25.5%)
Figure 1 CHAID algorithms. (A) STBSG data set and (B) FSG data set.
Table 4 Early death rate according to probability tree analysis and
algorithm accuracy in both cohorts
Groups STBSG FSG
PS¼0 1201 40 (3.3) 165 1 (0.6)
PS¼1 1361 129 (9.4) 156 11 (7.1)
PS X2 and non-grade III 195 38 (13.9) 16 2 (12.5)
PS X2 and grade III 110 40 (36.4) 10 1 (10.0)
Area under receiver
operator curve
0.86 (0.84–0.87) 0.89 (0.86–0.93)
STBSG (n¼2867) FSG (n¼347)
Early death Other Early death Other
PS X2 78 227 3 23
PS¼(0–1) 169 2393 12 309
Accuracy (%) (95% CI) 86.2 (84.5–87.4) 89.0 (86.5–93.5)
Abbreviations: STBSG¼Soft Tissue and Bone Sarcoma Group; FSG¼French
Sarcoma Group; CI¼confidence interval; PS¼performance status.
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Figure 2 Area under receiver operator curves. (A) STBSG database.
Grey dotted line: logistic regression-based scoring; black dotted line: w
2
interaction detection algorithm; black line: performance status alone as
prognostic model (this line completely covers the CHAID algorithm line).
(B) FSG database. Grey dotted line: logistic regression-based scoring; black
dotted line: w
2 interaction detection algorithm; black line: performance
status alone as prognostic model (this line completely covers the CHAID
algorithm line).
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models for early death had previously been used for analysis of
other PFs. Van Glabbeke et al (1999) found that the following
factors were associated with OS in patients who received doxorubicin:
PS (HR¼1.51, Po0.0001), liver metastasis (HR¼1.46, Po0.0001),
histological grade (HR¼1.24, P¼0.0002), time since initial
diagnosis (HR¼0.92, P¼0.0004) and age (HR¼1.10,
P¼0.0045). In the same study, the following parameters were
associated with objective response: liver metastasis (OR¼0.38,
Po0.0001), age (OR¼0.83, P¼0.0024) and histological grade
(OR¼1.35, P¼0.051). Blay et al (2003) identified the following
parameters as factors associated with long-term survival: PS
(OR¼2.02, P¼0.0235), grade (OR¼2.18, P¼0.0009), female
(OR¼0.43, P¼0.0291) and complete response obtained after
first-line treatment (OR¼0.11, P¼0.0001). The originality of this
work is that the relative weight of each PF and its interaction were
studied in a very large data set using two complementary
approaches, and the identified factors were validated in an
independent cohort. At the end, the prognostic value of PS
outweighs all other clinical parameters.
The limitations of this study are related to its retrospective
nature. For example, grade scoring and pathological classification
change during the study period. The prognostic value of grade
scoring is not established for some particular histological sub-
types (such as clear cell sarcoma, epithelioid sarcoma, angiosarco-
ma and so on). Moreover, the parameters used herein are the basic
clinical variables. For other tumour types, more elaborate and
sophisticated scores have been published, which integrate other
parameters such as lymphocyte count, LDH level or albumin
(Geraci et al, 2006; Kelly et al, 2007; Arkenau et al, 2008; Penel
et al, 2008, 2009). These parameters were not available in a
sufficiently large section of the STBSG cohorts and could not be
explored in the present study. The additional value of these
biological parameters should be evaluated. Furthermore, one could
argue that the development of prognostic model for early death
might be more relevant in patients failing first-line chemotherapy
and candidates for second-line treatment. We plan this second
analysis. Moreover, we ignore the precise cause of the death in
both databases, especially the incidence of toxic death vs death
caused by progressive disease.
Despite its subjective nature, estimation of general condition by
PS remains one of the most powerful PF in advanced/metastatic
STS patients. Nevertheless, PS is not suitable for disabled and/or
patients who suffer with persistent pain, for example, patients
treated with previous mutilating surgical procedure. There are
several scales available for scoring PS: the WHO-PS scale, the
ECOG-PS scale or the Karnofsky PS scale. These different scales
can generate discrepancies for evaluation of PS. It is well known
that physicians overestimate both PS and life expectancy (Parkes,
1972; Evans and McCarthy, 1985; Christakis and Lemont, 2000;
Ando et al, 2001). Ando et al (2001) had demonstrated that nurses
and patients themselves estimate more accurately the actual PS
than physicians.
Nevertheless, regarding its prognostic value, this variable has to be
taken into account in future clinical trials, for example, as stratification
factors at inclusion in randomised trials. For clinical decision making,
both models developed are far from ideal. The probability of early
death for a patient with PS X2i sB11–24% compared with 0–3% for
those with PS¼0 (Figure 1). In everyday practice, this does not imply
that all patients with PS X2 should be denied palliative chemotherapy
per se, but the high risk of an early death and the potential lack of
benefit from treatment should be discussed with the patient before a
decision is made to proceed with chemotherapy. Further studies are
warranted to develop and validate more accurate prognostic models, if
possible based on objectively measurable variables (such as biological
parameters) and excluding PS.
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